SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Aimmune Therapeutics, Inc. (Nasdaq -AIMT)

BALA CYNWYD – August 31, 2020 /Access Wire/ – Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Aimmune Therapeutics, Inc. (“Aimmune” or the “Company”) (Nasdaq -AIMT) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the Company’s agreement with Swiss food giant, Nestle for Nestle to acquire all of the outstanding shares of Aimmune common stock that it does not already own for only $34.50 per share in cash.

The investigation concerns whether the Aimmune Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Nestle is paying too little for the Company. For example, the deal consideration is below the 52-week high of $37.00 for Aimmune stock and at least one wall street analyst has set a price target of $66.00 per share for Aimmune.

If you own shares of Aimmune stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, or call toll free 877-534-2590.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.